Diagnos
DIAGNOS Inc. is a Canadian medical AI company that commercializes the CARA platform, using deep learning to analyze retinal images for early detection of eye diseases and systemic conditions, serving optometry clinics, hospital networks, and optical industry partners such as EssilorLuxottica across 16 countries.
- Company typePublic
- Founded1998
- HeadquartersBrossard, Canada
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Diagnos does
DIAGNOS Inc. is a Canadian medical AI company headquartered in Brossard, Quebec, that develops and commercializes the CARA System, an AI platform for analyzing retinal (fundus) photographs to enable early detection of eye diseases such as diabetic retinopathy, age-related macular degeneration, and glaucoma, as well as systemic conditions detectable through retinal imaging. The technology is built on proprietary deep learning and computer vision models applied to standard fundus camera images, allowing integration into existing clinical optometry workflows without specialized hardware. The product portfolio includes the CARA System (core clinical product), FLAIRE (a complementary AI eye health diagnostics platform), Nova Cloud Platform (real-time cloud-based image analysis), and the legacy RetinaCare product line.
The company generates revenue through enterprise agreements with clinics and hospital networks and channel partnerships with major optical industry players - notably EssilorLuxottica and IRIS - distributing CARA across global clinic and retail optical networks. Internationally, DIAGNOS operates a cloud-based deployment model that supports its footprint of 235 equipped centers, 140 clinics across 16 countries, and assessment of over 400,000 patients to date. Regulatory positioning includes cleared commercialization in the United States (legacy CARA), pending Health Canada Class II license submission (June 2026), and pending Saudi Arabia SFDA review (January 2026).
DIAGNOS is publicly traded on the TSX Venture Exchange (ADK) and OTCQB (DGNOF), with reported headcount of 11-50 employees. Its strategic posture emphasizes an academic-industry hybrid model: an AI research collaboration with École de Technologie Supérieure (ÉTS) secured over C$1.0 million in federal funding in February 2026 to advance next-generation retinal AI algorithms under a dedicated research chair. Multiple private placements in late 2025 (totaling approximately C$6 million) are funding regulatory, product development, and commercial initiatives ahead of anticipated multi-jurisdictional approvals.
Diagnos firmographics
Firmographics- Name
- Diagnos
- Legal name
- DIAGNOS Inc.
- Website
- https://diagnos.com
- Company type
- Public
- Founded year
- 1998
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- DIAGNOS Inc. is a Canadian medical AI company that commercializes the CARA platform, using deep learning to analyze retinal images for early detection of eye diseases and systemic conditions, serving optometry clinics, hospital networks, and optical industry partners such as EssilorLuxottica across 16 countries.
- Ownership category
- akta.pro rank
Diagnos industry classification
Industry- Product category
- AI Medical Imaging & Diagnostics
- NAICS
- Software Publishers (5132)
- SIC
- Measuring & Controlling Devices, Nec (3829)
- akta.pro primary industry
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
- akta.pro secondary industries
- Medical Imaging AI (HDAAAEAH), Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography) (HLAHAJAB), Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty) (HLAHAJAI)
Keywords
Where Diagnos is headquartered
LocationHeadquarters
- HQ city
- Brossard
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Diagnos business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Others
Revenue model
- AI-based health screening services: DIAGNOS generates revenue through the commercialization of its AI-powered eye disease detection platform (CARA System), providing analysis services to clinical and hospital partners. The company is pursuing regulatory approvals in multiple jurisdictions to enable broad commercial deployment.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
Diagnos product offering
Product offeringCore offering
DIAGNOS develops and commercializes the CARA System, an AI-powered retinal image analysis platform that uses deep learning and computer vision to detect eye diseases (diabetic retinopathy, age-related macular degeneration, glaucoma) and systemic conditions from standard fundus camera images. The platform is deployed via cloud-based real-time analysis across optometry clinics, hospital networks, and optical retail partners in 16 countries.
Product overview
DIAGNOS offers a unified AI healthcare platform centered on the CARA retinal analysis system, which detects eye diseases through fundus photography. The portfolio includes the FLAIRE AI platform for broader eye health diagnostics and the Nova Cloud Platform for real-time cloud-based image processing. These products work together to provide early detection of retinal diseases, with CARA serving as the primary clinical product and the other platforms supporting distribution and analysis capabilities across 140+ clinics in 16 countries.
Differentiator
Problem solved
Functional benefit
Brands
- CARA: AI-powered platform for early detection of eye diseases through fundus photography image analysis, used for retinal disease detection and systemic condition screening across clinical optometry workflows.
- FLAIRE
- RetinaCare
Products and services
- CARA System AI-powered retinal analysis platform that detects retinal diseases (diabetic retinopathy, age-related macular degeneration, glaucoma) and systemic conditions from standard fundus camera images, integrated directly into clinical optometry workflows. Deployed in 140+ clinics across 16 countries.
- Nova Cloud Platform Cloud-based real-time medical analysis platform enabling remote processing of retinal images, supporting CARA system deployment in clinical environments without requiring on-premise infrastructure.
Quantifiable outcome
- 500,000+ retinal images analyzed to date
- +4 more outcomes
Companies that use Diagnos
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Diagnos technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature3 records
Diagnos partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- École de Technologie Supérieure (ÉTS)coreDIAGNOS and ÉTS Montréal entered into a research collaboration that secured over C$1.0 million in federal funding in February 2026 to advance next-generation retinal AI algorithms. The partnership includes the establishment of a dedicated AI research chair at ÉTS, led by Dr. Ismail Ben Ayed, DIAGNOS's Chief AI Scientist. The collaboration drives innovation in AI models for medical image analysis, with published clinical validation across multiple sites.
- EssilorLuxotticacoreDIAGNOS has an established business relationship with EssilorLuxottica, one of the world's largest optical companies, to distribute its CARA AI platform through the company's global clinic and optical retail network. The partnership is part of DIAGNOS's strategy to achieve large-scale commercial deployment through industry leaders.
- IRIScoreDIAGNOS has a business relationship with IRIS for distribution of AI-powered retinal analysis technology through IRIS's network of eye care clinics and optical retail locations, enabling market expansion through established optical distribution channels.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
Diagnos competitors and assessment
Company assessmentBroad incumbents
- Carl Zeiss Meditec: Global leader in ophthalmic devices and diagnostic instruments with growing AI/data portfolio. Represents the resource-rich incumbent that DIAGNOS competes against for clinical adoption.
- Verily (Alphabet): Alphabet-owned health technology company with retinal AI/diabetic retinopathy programs and deep learning expertise. Represents well-capitalized AI competition in retinal screening.
- Optos (Nikon): Manufacturer of ultra-widefield retinal imaging devices now owned by Nikon. Competes in the retinal imaging workflow where CARA sits as the AI analysis layer.
- Topcon Healthcare: Major ophthalmic device manufacturer (OCT, fundus cameras) integrating AI capabilities into its imaging ecosystem. Larger incumbent competing for the same clinical workflows as CARA.
Direct peers
- Digital Diagnostics (IDx): Pioneer of autonomous AI diagnosis with FDA-cleared IDx-DR for diabetic retinopathy. Direct competitor in the same regulatory and clinical category as CARA.
- AEYE Health: AI startup developing autonomous diabetic retinopathy screening with FDA-cleared products. Comparable target use case (primary care screening) and clinical workflow positioning to DIAGNOS.
- Eyenuk: AI medical device company with FDA-cleared EyeArt system for autonomous diabetic retinopathy screening. Most directly comparable to CARA on disease focus, regulatory pathway, and clinical workflow integration.
Others
- HeartFlow: AI medical imaging company using deep learning for non-invasive cardiovascular diagnostics. Comparable as a regulated AI imaging SaMD company with similar regulatory, reimbursement, and clinical adoption dynamics to CARA.
Emerging players
- Zebra Medical Vision (Nanox): AI medical imaging company (now part of Nanox) developing deep learning algorithms across multiple imaging modalities. Adjacent AI/ML imaging competitor with broader radiology footprint.
- Retina-AI Health: Emerging AI company focused on retinal disease detection from fundus and OCT images. Direct niche overlap with CARA but at an earlier commercialization stage.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Diagnos social profiles
Digital presenceDiagnos compliance and trust
Trust signalCompliance3 records
Diagnos financial estimates
Financial estimateRevenue estimate
Valuation estimate
Diagnos leadership team
Management profileNumber of profiles
Profiles13 records
Diagnos funding detail
Funding detailFunding overview
Funding rounds19 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Diagnos M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Diagnos
What does Diagnos do?
DIAGNOS develops and commercializes the CARA System, an AI-powered retinal image analysis platform that uses deep learning and computer vision to detect eye diseases (diabetic retinopathy, age-related macular degeneration, glaucoma) and systemic conditions from standard fundus camera images. The platform is deployed via cloud-based real-time analysis across optometry clinics, hospital networks, and optical retail partners in 16 countries.
Is Diagnos a public or private company?
Diagnos is a public company. It is classified as public and is currently operating.
When was Diagnos founded?
Diagnos was founded in 1998. It employs 11 to 50 people.
Where is Diagnos based?
Diagnos is headquartered in Brossard, Canada, in the North America region.
How does Diagnos make money?
One revenue line is on record: AI-based health screening services.
Who are Diagnos's main competitors?
Broad incumbents on record are Carl Zeiss Meditec, Verily (Alphabet), Optos (Nikon) and Topcon Healthcare. Direct peers are Digital Diagnostics (IDx), AEYE Health and Eyenuk. HeartFlow is listed as an others. Emerging players are Zebra Medical Vision (Nanox) and Retina-AI Health.
Does Diagnos have an API?
No public API is recorded for Diagnos.
What industry is Diagnos in?
Diagnos's product category is AI Medical Imaging & Diagnostics. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 5132 and its SIC code is 3829.